Switzerland reviews third anti-viral Covid vaccine
The race is on worldwide to provide the first Covid-19 vaccine
Copyright 2020 The Associated Press. All Rights Reserved.
The Swiss therapeutics products agency Swissmedic has started a review of another anti-Covid 19 vaccine – this time from United States biotech firm Moderna - in the rolling submission procedure.
This content was published on
2 minutes
Keystone-SDA/Swissmedic/SWI swissinfo.ch/ilj
This is the third authorisation procedure submitted in Switzerland for a vaccine against the novel coronavirus.
“The rolling submission procedure for mRNA-1273 is based on the initially submitted data packages on the preclinical situation and quality, as well as on preliminary clinical data. In a rolling review, the data can be evaluated as soon as they become available. The companies can then submit the latest data continuously without having to wait for the conclusive results from all studies,” Swissmedic said on FridayExternal link.
Swissmedic can thus obtain an initial picture of the benefit-risk profile of the vaccine candidates before the authorisation studies are completed (Phase III studies). This accelerates the review process while at the same time “preserving the same level of careful checking of all requirements relating to safety, efficacy and quality”, it explained.
The agency is already reviewing authorisation applications for Covid-19 vaccines from the companies AstraZeneca and Pfizer/BioNTech.
Vaccine strategy
On Wednesday Swiss government announced that it had earmarked an additional CHF100 million ($111 million) to buy an anti-Covid vaccine.
Interior Minister Alain Berset said the aim was to provide a “safe and efficient product of high-quality” for the population in Switzerland. The allocation of funds comes on top of CHF300 million approved earlier this year.
So far, Switzerland has assured reservations for about 13 million doses of prospective vaccines from AstraZeneca and Moderna and an international programme by the World Health OrganizationExternal link (WHO). It is also in negotiations with Pfizer/BioNTech about assuring delivery. Swissmedic has to examine and approve any product before it is distributed.
Health officials estimate about 60-70% of the population must be inoculated against the new coronavirus to get the pandemic under control.
Coronavirus infections in Switzerland rose by 6,739, the federal health authorities said on Friday. The death toll increased by 97.
More
More
Swiss stump up more cash to buy a Covid-19 vaccine
This content was published on
Interior Minister Alain Berset, who announced the news on Wednesday, said the aim was to provide a “safe and efficient product of high-quality” for the population in Switzerland. The allocation of funds comes on top of CHF300 million approved earlier this year. So far, Switzerland has assured reservations for about 13 million doses of prospective…
Uri voters clear path for hotel and marina complex in central Switzerland
This content was published on
Voters in canton Uri in central Switzerland have rejected a Green Party initiative aimed at regulating the development of the lakeside site in Isleten.
Valais voters reject plan to achieve carbon neutrality by 2040
This content was published on
Voters in canton Valais in southern Switzerland have turned down a proposal for the region to achieve carbon neutrality by 2040.
Swiss central banker wants to boost equity to head off risks
This content was published on
Equity levels at the Swiss National Bank (SNB) are much too low for the risks its large balance sheet poses, according to Martin Schlegel.
Beer sales in Switzerland watered down by bad weather
This content was published on
The past brewing year fell through in Switzerland, partly due to the bad weather. Beer sales shrank again. For the first time, per capita consumption fell below the 50 liter mark.
This content was published on
The Swiss therapeutic products agency has begun reviewing another anti-Covid 19 vaccine in the rolling submission procedure.
This content was published on
Swiss drug authority Swissmedic has begun evaluating the so-called “Covid-19 Vaccine AstraZeneca”. It is the first time that a drugmaker has presented a coronavirus vaccine for approval in Switzerland.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.